Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc. a clinical-stage biopharmaceutical company engages in the discovering development and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463) a CNS-penetrant soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat an orally administered systemic sGC stimulator which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics Inc. for the development manufacture medical affairs and commercialization of pharmaceutical products including pharmaceutical compound and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge Massachusetts.